IOBT - IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting | Benzinga
- New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. The poster will include nonclinical data related to IO Biotech's lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study.
"We are excited with our new nonclinical data clearly demonstrating how the dual antigen vaccine IO102-IO103 differentially contribute to the anti-tumor effect: while IO102 treatment results in the reduction of the immune suppression in the TME, IO103 appears to impact by enhancement of T effector function," said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. "These findings further support the potential that co-administration of the dual antigen vaccine IO102-IO103 can benefit patients due to its impact on two separate immune resistance pathways, IDO1 and PD-L1, respectively."
Presentation Details
Poster Title: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models
Session Title: Vaccines, Antigens, and Antigen Presentation 1
Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM
Location: Poster Section 5
Poster Board Number: 5
Poster Abstract Number: 4094
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed ...